nach oben

Erschienen in:

01.05.2011 | Original Article

Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma

verfasst von: Mario Airoldi, Pietro Gabriele, Anna Maria Gabriele, Massimiliano Garzaro, Luca Raimondo, Fulvia Pedani, Fabio Beatrice, Giancarlo Pecorari, Carlo Giordano

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Aim of this study was the clinical evaluation of carboplatin–taxol combination in a neoadjuvant and concomitant setting with conventional radiotherapy in loco-regionally advanced nasopharyngeal carcinoma (A-NPC).

Methods

Thirty patients were treated with three cycles of carboplatin (AUC6) plus taxol (175 mg/m²) on day 1 every 3 weeks, followed by weekly carboplatin (AUC1) plus Taxol (60 mg/m2) and concomitant radiotherapy (70 Gy).

Results

We observed the objective complete response rates of 33% (after chemotherapy) and 87% (after chemo-radiotherapy). Treatment tolerability and toxicity were controllable. Three- and five-year progression-free survival were 80 and 75%, respectively, and 3- and 5-year overall survival were 85 and 80% (follow-up 49.5 months). Five-year loco-regional control was 90.3%, and five-year distant metastases–free survival was 85%.

Conclusions

Neoadjuvant chemotherapy with such protocol represents a feasible, efficient treatment for patients with A-NPC, ensuring excellent loco-regional disease control and overall survival with low incidence of distant metastases.

Guigay J, Temam S, Bourhis J et al (2006) Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy. Ann Oncol 17(suppl 10):x304–x307PubMedCrossRef

International Nasopharynx Cancer Study Group (1996) VUMCA I trial: preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, belomycin) plus radiotherapy vs. radiotherapy alone in stage IV (N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 35:463–469CrossRef

Chua DT, Sham JS, Choy D et al (1998) Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal arcinoma. Cancer 83:2270–2283PubMedCrossRef

Ma J, Mai HQ, Hong MH et al (2001) Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19:1350–1357PubMed

Haeryama M, Sakata K, Shirato H et al (2002) A prospective randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in advanced nasopharyngeal carcinoma. Cancer 94:2217–2223CrossRef

Oh JL, Vokes EE, Kies MS et al (2003) Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 14:564–569PubMedCrossRef

Rischin D, Corry J, Smith J et al (2002) Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 20:1845–1852PubMedCrossRef

Al-Amro A, Al Rajhi N, Khafaga J et al (2005) Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 62(2):508–513PubMedCrossRef

Airoldi M, Gabriele AM, Garzaro M et al (2009) Induction Chemotherapy with Cisplatin and Epirubicin followed by radiotherapy and concurrent Cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. Radiother Oncol 92(1):105–110PubMedCrossRef

10.

Airoldi M, Pedani F, Marchionatti S et al (2002) Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori 88(4):273–276PubMed

11.

Tan EH, Khoo KS, Wee J et al (1999) Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 10(2):235–237PubMedCrossRef

12.

Yeo W, Leung TW, Chan AT et al (1998) A phase II study combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 34(13):2027–2031PubMedCrossRef

13.

Seidman AD (1998) One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index. Oncology 12:19–22PubMed

14.

Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61:1107–1116PubMedCrossRef

15.

Baujat B, Audry H, Bourhis J et al (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized clinical trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47–56PubMedCrossRef

16.

Chua DT, Ma J, Sham JS et al (2005) Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 23:1118–1124PubMedCrossRef

17.

Chan AT, Teo PM, Leung TW et al (1995) A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33:569–577PubMedCrossRef

18.

Chan ATC, Ma BBY, Lo D et al (2004) Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr Virus DNA. J Clin Oncol 22;15:3053–3060

19.

Chitapanarux I, Lorvidhaya W, Kamnerdsupaphon P et al (2007) Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non inferiority, open trial. Eur J Cancer 43(9):1399–1406PubMedCrossRef

20.

Kramer NM, Horwitz EM, Cheng J et al (2005) Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 27(5):406–414PubMedCrossRef

21.

Spencer SA, Harris J, Weeler RH et al (2008) Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 30(3):281–288PubMedCrossRef

22.

Langer CJ, Harris J, Horwitz EM et al (2007) Phase II study of low dose paclitaxel and cisplatin in combination with split course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 25(30):4800–4805PubMedCrossRef

Titel: Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma
verfasst von: Mario Airoldi
Pietro Gabriele
Anna Maria Gabriele
Massimiliano Garzaro
Luca Raimondo
Fulvia Pedani
Fabio Beatrice
Giancarlo Pecorari
Carlo Giordano
Publikationsdatum: 01.05.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1399-5

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma